Search

Displaying results 4421 - 4430 of 10000 in total
  1. Drug

    ZYC300

    go.drugbank.com/drugs/DB04986
    Investigational

    It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells. … ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles.

  2. Drug

    Motretinide

    go.drugbank.com/drugs/DB13368
    Experimental

    Categories: Retinoids for Topical Use in Acne
  3. Drug

    Hymecromone

    go.drugbank.com/drugs/DB07118
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels … Linifanib is intended for the treatment of hematologic malignancies and the solid tumors.

    Synonyms: UREA, N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N'-(2-FLUORO-5-METHYLPHENYL)-, N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea
  5. Drug

    VX-148

    go.drugbank.com/drugs/DB06103
    Experimental

    The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes. VX-148 is a developed for the treatment of autoimmune diseases. … VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH).

  6. Drug

    CLX-0921

    go.drugbank.com/drugs/DB05854
    Experimental

    CLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. … It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to insulin.

  7. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  8. Drug

    Besifovir dipivoxil

    go.drugbank.com/drugs/DB05020
    Investigational

    Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. … Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.

  9. Drug

    Cositecan

    go.drugbank.com/drugs/DB05806
    Investigational

    Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.

  10. Drug

    Omapatrilat

    go.drugbank.com/drugs/DB00886
    Experimental

    The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling. … Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE).

    Categories: Agents Acting on the Renin-Angiotensin System